Weiss Asset Management
VC Fund
Boston, United States
Weiss Asset Management is a VC fund in Boston focused on Health Care and Biotechnology. Weiss Asset Management develops proprietary value-based investment strategies. Weiss Asset Management is an organization that bases its investment choices on facts and sound reasoning. Through in-depth fundamental research, statistical analysis, and an analytically rigorous approach to decision-making, the company collaborates to solve issues andidentify undervalued assets.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Weiss Asset Management invests in
Stages Weiss Asset Management invests in
Countries Weiss Asset Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Weiss
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 4 (50%)
- Biotechnology 4 (50%)
- Medical 2 (25%)
- Therapeutics 2 (25%)
- Bitcoin 1 (13%)
Country
- South Korea 3 (38%)
- United States 2 (25%)
- China 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Weiss
Founder & CEO, Chief Investment Officer
|
Founder & CEO, Chief Investment Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ionic Digital
|
Ionic Digital is an innovator in the bitcoin mining industry. | $400M / Venture - Series Unknown / Jun 26, 2026 | |
OliX Pharmaceuticals
|
OliX is a clinical stage biotechnology company, based on their own proprietary RNA interference (RNAi) technology regulating the expression of disease-causing genes. | $72.6M / Post-IPO Equity / Jun 02, 2026 | |
ROKIT Healthcare
|
ROKIT Healthcare provides hardware, software, and application support. Their custom fabrication technologies deliver solutions to the design, creation, and applications of three-dimensional systems. They provide suffering patients and humans with a hyper-personalized medical organ regeneration solution. They apply artificial intelligence and 3dbioprinting technology to regenerate the skin and cartilage organs through surgery for patients. | $42.5M / Post-IPO Equity / Mar 10, 2026 | |
Orum Therapeutics
|
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M / Post-IPO Equity / Dec 18, 2025 | |
Canaan Creative
|
Canaan Creative produces Blockchain servers and solutions for repetition ASIC chips. Our products are sold globally. | $72M / Post-IPO Equity / Nov 04, 2025 | |
Gossamer Bio
|
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focuson areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology. | $120M / Post-IPO Equity / Jul 13, 2022 | |
IronNet Cybersecurity
|
IronNet Cybersecurity is a network security company that allows enterprises and nations to defend against emerging threats in real time. The company is transforming how organizations secure their networks by delivering the first-ever Collective Defense platform operating at scale. Employing a high number of former NSA cybersecurity operators withoffensive and defensive cyber experience, IronNet integrates deep tradecraft knowledge into its industry-leading products to solve the most challenging cyber problems facing the world today. | $125M / Post-IPO Equity / Aug 27, 2021 | |
ATI Physical Therapy
|
ATI Physical Therapy is an outpatient orthopedic private practice that focuses on providing high-quality rehabilitation services. ATI distinguishes itself in the rehabilitation industry by taking a comprehensive, whole body approach with emphasis on hands-on, one-to-one care. ATI Physical Therapy was named the "Best Physical TherapyPractice" in the nation by Advance Magazine for performing exceptionally strong in all areas of assessment including patient care and growth, employee training and retention, services, community presence, facilities, and company expansion. | $300M / Post-IPO Equity / Jun 17, 2021 |
Co-Investors
Monashee Investment Management
2 deals together
ANDA Asset Management
1 deal together
AON Investment
1 deal together
ASEM Asset Management
1 deal together
Attestor
1 deal together
BH Digital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Weiss Asset Management invest in?
Weiss Asset Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity stage. Most of the 8 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Weiss Asset Management?
Public channels for Weiss Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Weiss Asset Management?
The team at Weiss Asset Management includes Andrew Weiss (Founder & CEO, Chief Investment Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
